Puma Biotechnology (PBYI) Stock Price, Quote & News

Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A fo...

Industry: Biotechnology

Sector: Healthcare

Phone: 424 248 6500

Website: www.pumabiotechnology.com

Address:

10880 Wilshire Boulevard, Suite 1700, Los Angeles, United States

PSDL75 Jul. 22 at 11:44 AM

$PBYI man, slowly but surely this is creeping up on a 5yr high...

0 · Reply

Bazzil Jul. 21 at 5:30 PM

$PBYI nice looking 1-yr and 5-yr chart.

0 · Reply

theiceman9081 Jul. 21 at 5:20 PM

$PBYI $9+ today. LET’S GOOOOOO

0 · Reply

Jonnyking Jul. 14 at 8:30 PM

$PBYI sold all my shares, bye bye PBYI, stuck with for almost 5 years for very minimum gain. It was painful process for 100% gain...

3 · Reply

NathanChase0000 Jul. 9 at 5:09 PM

$PBYI one of my better investments, other than Sandisk ofc

0 · Reply

Unicorn2020 Jul. 9 at 4:50 PM

$PBYI The stock cannot break out the way it should technically because 1) insiders are selling like crazy 2) no upgrade from analysts. None whatsoever. It looks like no one is interested in this company.

1 · Reply

NathanChase0000 Jul. 7 at 10:22 PM

$PBYI Dang, this thing is on a run.

0 · Reply

theiceman9081 Jul. 7 at 9:27 PM

$PBYI $11 let’s gooooo

0 · Reply

vu_jade Jul. 2 at 2:58 PM

$PBYI great chart

0 · Reply

theiceman9081 Jul. 2 at 2:25 PM

$PBYI 👏

0 · Reply

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results

Jun 3, 2026, 5:00 PM EDT - 2 months ago

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-05-07T22:49:05.000Z - 3 months ago

Puma Biotechnology reports Q1 adjusted EPS (4c) vs (10c) last year

2026-05-07T22:48:42.000Z - 3 months ago

Puma Biotechnology sees Q2 revenue $52M-$55M, one estimate $52M

2026-05-07T22:47:53.000Z - 3 months ago

Puma Biotechnology raises FY26 revenue view to $222M-$229M from $214M-$221M

May 7, 2026, 4:30 PM EDT - 3 months ago

Puma Biotechnology Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Puma Biotechnology Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Puma Biotechnology Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Puma Biotechnology Slides: Q1 2026

May 7, 2026, 4:05 PM EDT - 3 months ago

Puma Biotechnology Reports First Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Puma Biotechnology Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Puma Biotechnology Proxy statement: Proxy filing

Apr 23, 2026, 4:15 PM EDT - 3 months ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Puma Biotechnology Proxy statement: Proxy filing

Mar 2, 2026, 2:30 PM EST - 5 months ago

Puma Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-26T22:00:30.000Z - 5 months ago